Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.42 |
| ▸ | EDNRB | P24530 | 4/20 | 0.41 |
| ▸ | PPARG | P37231 | 6/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | TSPO | P30536 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498192 | 0.91 | RXRA (0.43) | PPARGRXRARXRBMRGPRX4 | |
| SCHEMBL6488966 | 0.89 | RXRA (0.41) | PPARGRXRARXRBMRGPRX4 | |
| SCHEMBL6497678 | 0.82 | PTPN11 (0.46) | PPARG | |
| SCHEMBL6489841 | 0.80 | PPARG (0.47) | PPARGRXRARXRBMRGPRX4 | |
| SCHEMBL6488456 | 0.79 | DCTPP1 (0.44) | PPARGRXRARXRBTSPO | |
| SCHEMBL6501593 | 0.78 | KDM4C (0.44) | — | |
| SCHEMBL6491243 | 0.78 | TLR7 (0.41) | EDNRBTAS1R3TAS1R1TSPO | |
| SCHEMBL6496733 | 0.78 | ALOX5AP (0.47) | PPARGRXRARXRBMRGPRX4 | |
| SCHEMBL6487982 | 0.78 | DCTPP1 (0.41) | PPARGRXRARXRBMRGPRX4 | |
| SCHEMBL6490645 | 0.78 | PTGDR (0.44) | PPARGRXRARXRBMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | AGTR1 2045/4885AGTR2 2247/4885EDNRB 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.